Werfen to acquire Immucor
Nov. 4, 2022—Werfen announced it has agreed to acquire Immucor from asset management firm TPG.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Thermo Fisher Scientific buys Binding Site
Oct. 31, 2022—Thermo Fisher Scientific announced today that it has entered into a definitive agreement to acquire the Binding Site Group from a shareholder group led by European private equity firm Nordic Capital.
Bio-Rad launches Exact Diagnostics CT/NG, STI run controls
Oct. 28, 2022—Bio-Rad Laboratories has launched two Exact Diagnostics products, CT/NG Positive Run Control, intended to be used with Chlamydia trachomatis and Neisseria gonorrhoeae molecular assays, and STI Negative Run Control, which monitors the absence of Chlamydia trachomatis and Neisseria gonorrhoeae in various molecular assays, the company says, and can be used to detect errors in laboratory testing procedures, including potential contamination events, while controlling for sample adequacy assessment.
FDA clears COVID-19 PCR test on Cobas 6800/8800 systems
Oct. 25, 2022—Roche announced that the FDA has granted 510(k) clearance for the Cobas SARS-CoV-2 Qualitative PCR test for use on the automated Cobas 6800 and Cobas 8800 systems.
ZeptoMetrix launches molecular QCs for women’s health
Oct. 19, 2022—ZeptoMetrix launched two vaginal molecular QC controls, NATtrol Vaginal Positive Control and NATtrol Vaginal Negative Control, for in vitro diagnostic use.
Indica, Hamamatsu to provide integrated DP workflows
Oct. 18, 2022—Indica Labs and Hamamatsu Photonics announced an agreement to maintain long-term interoperability between Indica Labs’ Halo AP software platform and Hamamatsu’s NanoZoomer series of scanners.
Sebia acquires Zeus Scientific
Oct. 17, 2022—Sebia announced the acquisition of Zeus Scientific, an in vitro diagnostic company based in Branchburg, NJ.
Bio-Rad introduces Unity Next Peer QC
Oct. 14, 2022—Bio-Rad Laboratories has launched Unity Next Peer QC, a quality control peer comparison software that provides instant access to peer reporting and comprehensive quality control data.
ZeptoMetrix releases flu, RSV, SARS-CoV-2 external run control
Oct. 13, 2022—ZeptoMetrix has released its NATtrol external run control for flu A and B, RSV B, and SARS-CoV-2, for research use only.
mTuitive, Gestalt partner to enhance pathology reporting
Oct. 11, 2022—mTuitive and Gestalt Diagnostics announced a partnership to enhance reporting for pathology laboratories.